GERON CORP Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
GERON CORP (GERN) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $286.35 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2025-11-07
- GERON CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $90.29M, a 38.36% increase year-over-year.
- GERON CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-06-30 was $97.18M, a 22.12% decline year-over-year.
- GERON CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-03-31 was $98.88M, a 1.55% decline year-over-year.
- GERON CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-12-31 was $81.14M, a 27.78% increase year-over-year.
- GERON CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $371.61M, a 25.50% increase from fiscal 2023.
- GERON CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $296.10M, a 7.61% decline from fiscal 2022.
- GERON CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $320.50M, a 29.24% increase from fiscal 2021.
- GERON CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2021 was $247.99M, a 23.83% increase from fiscal 2020.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-09-30 | $90.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $187.47M derived: sum of 2 quarters · filed 2025-11-07 | $286.35M 10-Q · filed 2025-11-07 | $367.49M derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-06-30 | $97.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $196.06M 10-Q · filed 2025-08-06 | $277.20M derived: sum of 3 quarters · filed 2025-08-06 | $342.46M derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-03-31 | $98.88M 10-Q · filed 2025-05-07 | $180.02M derived: sum of 2 quarters · filed 2025-05-07 | $245.28M derived: sum of 3 quarters · filed 2025-11-07 | $370.05M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-12-31 | $81.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $146.39M derived: sum of 2 quarters · filed 2025-11-07 | $271.17M derived: sum of 3 quarters · filed 2025-11-07 | $371.61M 10-K · filed 2025-02-27 |
| 2024-09-30 | $65.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $190.03M derived: sum of 2 quarters · filed 2025-11-07 | $290.47M 10-Q · filed 2025-11-07 | $353.97M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $124.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $225.22M 10-Q · filed 2025-08-06 | $288.71M derived: sum of 3 quarters · filed 2025-08-06 | $388.20M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $100.44M 10-Q · filed 2025-05-07 | $163.94M derived: sum of 2 quarters · filed 2025-05-07 | $263.43M derived: sum of 3 quarters · filed 2025-05-07 | $333.29M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $63.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $162.99M derived: sum of 2 quarters · filed 2025-02-27 | $232.85M derived: sum of 3 quarters · filed 2025-02-27 | $296.10M 10-K · filed 2025-02-27 |
| 2023-09-30 | $99.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $169.35M derived: sum of 2 quarters · filed 2024-11-07 | $232.60M 10-Q · filed 2024-11-07 | $412.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $69.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $133.12M 10-Q · filed 2024-08-08 | $312.91M derived: sum of 3 quarters · filed 2025-02-27 | $363.21M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $63.25M 10-Q · filed 2024-05-02 | $243.05M derived: sum of 2 quarters · filed 2025-02-27 | $293.35M derived: sum of 3 quarters · filed 2025-02-27 | $335.17M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $179.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $230.10M derived: sum of 2 quarters · filed 2025-02-27 | $271.92M derived: sum of 3 quarters · filed 2025-02-27 | $320.50M 10-K · filed 2025-02-27 |
| 2022-09-30 | $50.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $92.13M derived: sum of 2 quarters · filed 2023-11-02 | $140.71M 10-Q · filed 2023-11-02 | $210.13M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $41.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $90.41M 10-Q · filed 2023-08-03 | $159.83M derived: sum of 3 quarters · filed 2024-02-28 | $188.57M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $48.58M 10-Q · filed 2023-05-11 | $118.00M derived: sum of 2 quarters · filed 2024-02-28 | $146.74M derived: sum of 3 quarters · filed 2024-02-28 | $234.95M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $69.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $98.16M derived: sum of 2 quarters · filed 2024-02-28 | $186.37M derived: sum of 3 quarters · filed 2024-02-28 | $247.99M 10-K · filed 2024-02-28 |
| 2021-09-30 | $28.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $116.95M derived: sum of 2 quarters · filed 2022-11-07 | $178.57M 10-Q · filed 2022-11-07 | $249.88M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $88.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $149.83M 10-Q · filed 2022-08-11 | $221.14M derived: sum of 3 quarters · filed 2023-03-16 | $272.08M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $61.62M 10-Q · filed 2022-05-09 | $132.93M derived: sum of 2 quarters · filed 2023-03-16 | $183.87M derived: sum of 3 quarters · filed 2023-03-16 | $222.62M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $71.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $122.25M derived: sum of 2 quarters · filed 2023-03-16 | $161.00M derived: sum of 3 quarters · filed 2023-03-16 | $200.26M 10-K · filed 2023-03-16 |
| 2020-09-30 | $50.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $89.69M derived: sum of 2 quarters · filed 2021-11-09 | $128.95M 10-Q · filed 2021-11-09 | $173.22M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $38.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $78.01M 10-Q · filed 2021-08-16 | $122.28M derived: sum of 3 quarters · filed 2022-03-10 | $164.44M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $39.26M 10-Q · filed 2021-05-10 | $83.53M derived: sum of 2 quarters · filed 2022-03-10 | $125.69M derived: sum of 3 quarters · filed 2022-03-10 | $167.44M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $44.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $86.43M derived: sum of 2 quarters · filed 2022-03-10 | $128.18M derived: sum of 3 quarters · filed 2022-03-10 | $181.28M 10-K · filed 2022-03-10 |
| 2019-09-30 | $42.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $83.91M derived: sum of 2 quarters · filed 2020-11-05 | $137.01M 10-Q · filed 2020-11-05 | $176.51M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $41.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $94.85M 10-Q · filed 2020-08-06 | $134.35M derived: sum of 3 quarters · filed 2021-03-11 | $167.66M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $53.10M 10-Q · filed 2020-05-28 | $92.60M derived: sum of 2 quarters · filed 2021-03-11 | $125.91M derived: sum of 3 quarters · filed 2021-03-11 | $146.60M derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $39.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $72.81M derived: sum of 2 quarters · filed 2021-03-11 | $93.50M derived: sum of 3 quarters · filed 2021-03-11 | $110.66M 10-K · filed 2021-03-11 |
| 2018-09-30 | $33.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $54.00M derived: sum of 2 quarters · filed 2019-11-06 | $71.16M 10-Q · filed 2019-11-06 | $99.65M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $20.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $37.85M 10-Q · filed 2019-08-01 | $66.34M derived: sum of 3 quarters · filed 2020-03-12 | $94.89M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $17.16M 10-Q · filed 2019-05-02 | $45.65M derived: sum of 2 quarters · filed 2020-03-12 | $74.20M derived: sum of 3 quarters · filed 2020-03-12 | $102.50M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $28.49M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $57.04M derived: sum of 2 quarters · filed 2020-03-12 | $85.34M derived: sum of 3 quarters · filed 2020-03-12 | $122.98M 10-K · filed 2020-03-12 |
| 2017-09-30 | $28.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $56.85M derived: sum of 2 quarters · filed 2018-11-01 | $94.49M 10-Q · filed 2018-11-01 | $125.59M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $28.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $65.94M 10-Q · filed 2018-07-31 | $97.04M derived: sum of 3 quarters · filed 2019-03-07 | $132.76M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $37.64M 10-Q · filed 2018-05-10 | $68.74M derived: sum of 2 quarters · filed 2019-03-07 | $104.46M derived: sum of 3 quarters · filed 2019-03-07 | $132.61M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $31.10M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $66.82M derived: sum of 2 quarters · filed 2019-03-07 | $94.97M derived: sum of 3 quarters · filed 2019-03-07 | $138.05M 10-K · filed 2019-03-07 |
| 2016-09-30 | $35.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $63.87M derived: sum of 2 quarters · filed 2017-11-01 | $106.95M 10-Q · filed 2017-11-01 | $165.01M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-06-30 | $28.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $71.23M 10-Q · filed 2017-08-09 | $129.29M derived: sum of 3 quarters · filed 2018-03-16 | $179.04M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-03-31 | $43.08M 10-Q · filed 2017-05-09 | $101.14M derived: sum of 2 quarters · filed 2018-03-16 | $150.89M derived: sum of 3 quarters · filed 2018-03-16 | $192.97M derived: sum of 4 quarters · filed 2018-03-16 |
| 2015-12-31 | $58.05M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $107.80M derived: sum of 2 quarters · filed 2018-03-16 | $149.89M derived: sum of 3 quarters · filed 2018-03-16 | $202.38M 10-K · filed 2018-03-16 |
| 2015-09-30 | $49.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $91.84M derived: sum of 2 quarters · filed 2016-11-03 | $144.33M 10-Q · filed 2016-11-03 | $175.69M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $42.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $94.58M 10-Q · filed 2016-08-03 | $125.94M derived: sum of 3 quarters · filed 2017-03-01 | $154.33M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $52.49M 10-Q · filed 2016-05-05 | $83.85M derived: sum of 2 quarters · filed 2017-03-01 | $112.24M derived: sum of 3 quarters · filed 2017-03-01 | $136.54M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $31.36M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $59.75M derived: sum of 2 quarters · filed 2017-03-01 | $84.05M derived: sum of 3 quarters · filed 2017-03-01 | $101.41M 10-K · filed 2017-03-01 |
| 2014-09-30 | $28.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $52.69M derived: sum of 2 quarters · filed 2014-11-05 | $70.05M 10-Q · filed 2014-11-05 | $105.59M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | $24.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $41.66M 10-Q · filed 2014-08-11 | $77.20M derived: sum of 3 quarters · filed 2016-03-10 | $99.59M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | $17.36M 10-Q · filed 2015-05-07 | $52.90M derived: sum of 2 quarters · filed 2016-03-10 | $75.29M derived: sum of 3 quarters · filed 2016-03-10 | $98.61M derived: sum of 4 quarters · filed 2016-03-10 |
| 2013-12-31 | $35.54M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $57.92M derived: sum of 2 quarters · filed 2016-03-10 | $81.24M derived: sum of 3 quarters · filed 2016-03-10 | $108.84M 10-K · filed 2016-03-10 |
| 2013-09-30 | $22.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $45.71M derived: sum of 2 quarters · filed 2014-11-05 | $73.30M 10-Q · filed 2014-11-05 | $114.04M derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-06-30 | $23.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $50.92M 10-Q · filed 2014-08-11 | $91.66M derived: sum of 3 quarters · filed 2015-03-11 | $127.81M derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-03-31 | $27.59M 10-Q · filed 2014-05-01 | $68.34M derived: sum of 2 quarters · filed 2015-03-11 | $104.49M derived: sum of 3 quarters · filed 2015-03-11 | $131.12M derived: sum of 4 quarters · filed 2015-03-11 |
| 2012-12-31 | $40.74M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $76.89M derived: sum of 2 quarters · filed 2015-03-11 | $103.53M derived: sum of 3 quarters · filed 2015-03-11 | $141.02M 10-K · filed 2015-03-11 |
| 2012-09-30 | $36.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $62.78M derived: sum of 2 quarters · filed 2013-11-07 | $100.28M 10-Q · filed 2013-11-07 | $147.67M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $26.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $64.12M 10-Q · filed 2013-08-08 | $111.52M derived: sum of 3 quarters · filed 2014-03-17 | $157.42M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | $37.49M 10-Q · filed 2013-05-03 | $84.88M derived: sum of 2 quarters · filed 2014-03-17 | $130.78M derived: sum of 3 quarters · filed 2014-03-17 | $160.80M derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | $47.39M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $93.30M derived: sum of 2 quarters · filed 2014-03-17 | $123.31M derived: sum of 3 quarters · filed 2014-03-17 | $176.83M 10-K · filed 2014-03-17 |
| 2011-09-30 | $45.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $75.92M derived: sum of 2 quarters · filed 2012-11-02 | $129.44M 10-Q · filed 2012-11-02 | $152.56M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-06-30 | $30.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $83.54M 10-Q · filed 2012-08-03 | $106.66M derived: sum of 3 quarters · filed 2013-03-15 | $149.92M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-03-31 | $53.52M 10-Q · filed 2012-05-07 | $76.65M derived: sum of 2 quarters · filed 2013-03-15 | $119.90M derived: sum of 3 quarters · filed 2013-03-15 | |
| 2010-12-31 | $23.13M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $66.38M derived: sum of 2 quarters · filed 2013-03-15 | $137.32M 10-K · filed 2013-03-15 | |
| 2010-09-30 | $43.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $114.19M 10-Q · filed 2011-11-03 | ||
| 2010-06-30 | $70.94M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $120.52M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |